• RhNTA protein;
  • refolding;
  • two gradients;
  • purification;
  • chromatography


  1. Top of page
  2. Abstract
  3. References

RhNTA protein is a new thrombolytic agent which has potential medicinal and commercial value. Protein refolding is a bottleneck for large-scale production of valuable proteins expressed as inclusion bodies in Escherichia coli. The denatured rhNTA protein was refolded by an improved size-exclusion chromatography refolding process achieved by combining an increasing arginine gradient and a decreasing urea gradient (two gradients) with a size-exclusion chromatography refolding system. The refolding of denatured rhNTA protein showed that this method could significantly increase the activity recovery of protein at high protein concentration. The activity recovery of 37% was obtained from the initial rhNTA protein concentration up to 20 mg/mL. After refolding by two-gradient size-exclusion chromatography refolding processes, the refolded rhNTA was purified by ion-exchange and affinity chromatography. The purified rhNTA protein showed one band in SDS-PAGE and the specific activity of purified rhNTA protein was 110,000 U/mg. Copyright © 2008 John Wiley & Sons, Ltd.


  1. Top of page
  2. Abstract
  3. References
  • Arakawa T and Tsumoto K. The effects of arginine on refolding of aggregated proteins: not facilitate refolding, but suppress aggregation. Biochemical Biophysical Research Communication 2003; 304: 148152.
  • Batas B and Chaudhuri JB. Protein refolding at high concentration using size-exclusion chromatography. Biotechnology and Bioengineering 1995; 50: 1623.
  • Boyle MD and Lottenberg K. Plasminogen activation by invasive human pathogens. Journal of Thrombosis and Haemostasis 1997; 77: 110
  • Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein dye binding. Analytical Biochemistry 1976; 72: 248254.
  • Buchner J and Rudolph R. Purification and characterization of recombinant Fab-fragment produced in Escherichia coli. Journal of Biotechnology 1991; 9: 157162.
  • Clark ED, Schwarz E and Rudolph R. Inhibition of aggregation side reactions during in vitro protein folding. Methods in Enzymology 1999; 309: 217236.
  • Daisuke E, Ryusuke Y and Tsutomn A. Arginine as an effective additive in gel permeation chromatography. Journal of Chromatography A 2005; 1994: 4955.
  • Dong XY, Wang Y and Shi JH. Size-exclusion chromatography with an artificial chaperone system enhanced lysozyme renaturation. Enzyme and Microbial Technology 2002; 30: 792797.
  • Du D. A new thrombolytic agent and its prepared methods and application. Patent of China, no. 00112980.5, 2000
  • Ejima D, Yumioka R and Kumagai I. Effective elution of antibodies by arginine and arginine derivatives in affinity column chromatography. Analytical Biochemistry 2005; 345: 250257.
  • Eliana DBC. Refolding of recombinant proteins. Current Opinion in Biotechnology 1998; 9: 157163.
  • Gu ZY and Su ZG. Urea gradient size-exclusion chromatography enhanced the yield of lysozyme refolding. Journal of Chromatography A 2001; 918: 311318.
  • Knappik A and Pluckthun A. Engineered turns of recombinant antibody improve its in vivo folding. Protein Engineering 1997; 54: 333343
  • LiLie H, Schwarz E and Rudolph R. Advances in refolding of proteins produced in Escherichia coli. Current Opinion in Biotechnology 1998; 9: 497501.
  • Nguyen G and Samama M. New thromobolytic agent. Annals of Clinical Biochemistry 1987; 45: 212218.
  • Nordt TK and Moser M. Pharmacokinetics and pharmacodynamics of lanoteplase. Journal of Thrombosis and Haemostasis 1999; 82: 121123.
  • Ricker RD and Sandoval LA. Fast, reproducible size-exclusion chromatography of biological macromolecules. Journal of Chromatography A 1996; 743: 4350.
  • Smalling RW. A fresh look at the molecular pharmacology of plasminogen activators: from theory to test tube to clinical outcomes. American Journal of Health-System Pharmacy 1997; 54: 722.
  • Stellmach B and Qin JY. Enzyme Measurement. China Light Industry Press, 1992.
  • Stulik K and Pacakova V. Some potentialities and drawbacks of contemporary size-exclusion chromatography. Journal of Biochemical Biophysical Methods 2003; 56: 113.
  • Suenaga M, Ohmae H and Tsuji S. Renaturation of recombinant human neurotrophin-3 from inclusion bodies using a suppressor agent of aggregation. Biotechnology and Applied Biochemistry 1998; 28: 119124.
  • Toombs CF. New directions in thrombolytic therapy. Current Opinion in Pharmacology 2001; 1: 164168.
  • Tsumoto K, Ejima D and Kumagai I. Practical considerations in refolding protein from inclusion bodies. Protein Expression and Purification 2003a; 28: 18.
  • Tsumoto K, Umestsu M and Kumagai I. Solubilization of active green fluorescent protein from insoluble particles by guanidine and arginine. Biochemical Biophysical Research Communication 2003b; 312: 13831386.
  • Tsutomu A, Daisuke E and Kouhei T. Improved performance of column chromatography by arginine: dye-affinity chromatography. Protein Expression and Purification 2007; 52: 410414.
  • Umetsu M, Tsumoto K and Hara M. How additives influence the refolding of immunoglobulin-folded proteins in s stepwise dialysis system: spectroscopic evidence for highly efficient refolding of a single-chain FV fragment. Biological Chemistry 2003; 278: 89798987.
  • Umetsu M, Tsumoto K and Nitta S. Nondenaturing solubilization of beta2 microglobulin from inclusion bodies by l-arginine. Biochemical Biophysical Research Communication 2005; 328: 189197.
  • Weber CJ. A modification of Sakaguchi's reaction for the determination of arginine. Biological Chemistry 1930; 86: 217222.
Abbreviations used



oxidized glutathione


reduced glutathione


inclusion bodies


human tissue-type plasminogen activator